Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality

被引：8

作者：

Chan, X. H. S. ^{[1
,2
]}

O'Connor, C. J. ^{[1
]}

Martyn, E. ^{[1
,3
]}

Clegg, A. J. ^{[1
]}

Choy, B. J. K. ^{[1
]}

Soares, A. L. ^{[1
]}

Shulman, R. ^{[4
,5
]}

Stone, N. R. H. ^{[1
]}

De, S. ^{[1
]}

Bitmead, J. ^{[6
]}

Hail, L. ^{[6
]}

Brealey, D. ^{[4
,7
]}

Arulkumaran, N. ^{[4
,7
]}

Singer, M. ^{[4
,7
]}

Wilson, A. P. R. ^{[1
]}

机构：

[1] Univ Coll London NHS Fdn Trust, Dept Clin Microbiol, London, England

[2] Univ Oxford, Big Data Inst, Nuffield Dept Med, Oxford, England

[3] London Sch Hyg & Trop Med, London, England

[4] Univ Coll London NHS Fdn Trust, Dept Crit Care, London, England

[5] Univ Coll London NHS Fdn Trust, Dept Pharm, CMORE, London, England

[6] Univ Coll London NHS Fdn Trust, Dept Infect Control, London, England

[7] UCL, Bloomsbury Inst Intens Care Med, London, England

来源：

JOURNAL OF HOSPITAL INFECTION | 2022年 / 124卷

关键词：

COVID-19; Bacteraemia; Pseudomonas aeruginosa; Antimicrobial stewardship; Co-infection; BLOOD-STREAM INFECTIONS; SURVEILLANCE; ENGLAND;

D O I：

10.1016/j.jhin.2022.03.007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Background: The COVID-19 pandemic increased the use of broad-spectrum antibiotics due to diagnostic uncertainty, particularly in critical care. Multi-professional communication became more difficult, weakening stewardship activities. Aim: To determine changes in bacterial co-/secondary infections and antibiotics used in COVID-19 patients in critical care, and mortality rates, between the first and second waves. Methods: Prospective audit comparing bacterial co-/secondary infections and their treatment during the first two waves of the pandemic in a single-centre teaching hospital intensive care unit. Data on demographics, daily antibiotic use, clinical outcomes, and culture results in patients diagnosed with COVID-19 infection were collected over 11 months. Findings: From March 9th, 2020 to September 2nd, 2020 (Wave 1), there were 156 patients and between September 3rd, 2020 and February 1st, 2021 (Wave 2) there were 235 patients with COVID-19 infection admitted to intensive care. No significant difference was seen in mortality or positive blood culture rates between the two waves. The proportion of patients receiving antimicrobial therapy (93.0% vs 81.7%; P < 0.01) and the duration of meropenem use (median (interquartile range): 5 (2-7) vs 3 (2-5) days; P = 0.01) was lower in Wave 2. However, the number of patients with respiratory isolates of Pseudomonas aeruginosa (4/156 vs 21/235; P < 0.01) and bacteraemia from a respiratory source (3/156 vs 20/235; P < 0.01) increased in Wave 2, associated with an outbreak of infection. There was no significant difference between waves with respect to isolation of other pathogens. Conclusion: Reduced broad-spectrum antimicrobial use in the second wave of COVID-19 compared with the first wave was not associated with significant change in mortality. (C) 2022 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

引用

页码：37 / 46

页数：10

共 23 条

[11]

Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]

[12]

Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0

[13] Defining COVID-19-associated pulmonary aspergillosis: systematic review and meta-analysis [J].

Kariyawasam, Ruwandi M. ;

Dingle, Tanis C. ;

Kula, Brittany E. ;

Vandermeer, Ben ;

Sligl, Wendy, I ;

Schwartz, Ilan S. .

CLINICAL MICROBIOLOGY AND INFECTION, 2022, 28 (07) :920-927

[14] ICU-acquired bloodstream infections in critically ill patients with COVID-19 [J].

Kokkoris, S. ;

Papachatzakis, I. ;

Gavrielatou, E. ;

Ntaidou, T. ;

Ischaki, E. ;

Malachias, S. ;

Vrettou, C. ;

Nichlos, C. ;

Kanavou, A. ;

Zervakis, D. ;

Perivolioti, E. ;

Ranellou, K. ;

Argyropoulou, A. ;

Zakynthinos, S. ;

Kotanidou, A. ;

Routsi, C. .

JOURNAL OF HOSPITAL INFECTION, 2021, 107 :95-97

[15] Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients [J].

Kooistra, Emma J. ;

van Berkel, Miranda ;

van Kempen, Noortje F. ;

van Latum, Celine R. M. ;

Bruse, Niklas ;

Frenzel, Tim ;

van den Berg, Maarten J. W. ;

Schouten, Jeroen A. ;

Kox, Matthijs ;

Pickkers, Peter .

CRITICAL CARE, 2021, 25 (01)

[16]

McMillan T, 2021, J INFECT, P83, DOI [10.1016/j.inf.2021.09.010, DOI 10.1016/J.INF.2021.09.010]

[17]

Public Health England, 2020, COVID 19 GUID HLTH P

[18] Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study [J].

Russell, Clark D. ;

Fairfield, Cameron J. ;

Drake, Thomas M. ;

Turtle, Lance ;

Seaton, R. Andrew ;

Wootton, Dan G. ;

Sigfrid, Louise ;

Harrison, Ewen M. ;

Docherty, Annemarie B. ;

de Silva, Thushan, I ;

Egan, Conor ;

Pius, Riinu ;

Hardwick, Hayley E. ;

Merson, Laura ;

Girvan, Michelle ;

Dunning, Jake ;

Nguyen-Van-Tam, Jonathan S. ;

Openshaw, Peter J. M. ;

Baillie, J. Kenneth ;

Semple, Malcolm G. ;

Ho, Antonia .

LANCET MICROBE, 2021, 2 (08) :E354-E365

[19] Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit [J].

Russo, Alessandro ;

Gavaruzzi, Francesca ;

Ceccarelli, Giancarlo ;

Borrazzo, Cristian ;

Oliva, Alessandra ;

Alessandri, Francesco ;

Magnanimi, Eugenia ;

Pugliese, Francesco ;

Venditti, Mario .

INFECTION, 2022, 50 (01) :83-92

[20] Antibiotic prescribing for respiratory tract infection in patients with suspected and proven COVID-19: results from an antibiotic point prevalence survey in Scottish hospitals [J].

Seaton, R. Andrew ;

Cooper, Lesley ;

Gibbons, Cheryl L. ;

Malcolm, William ;

Choo-Kang, Brian ;

Griffith, David ;

Dundas, Stephanie ;

Brittain, Suzanne ;

Hamilton, Kayleigh ;

Jeffreys, Danielle ;

McKinney, Rachel ;

Guthrie, Debbie ;

Sneddon, Jacqueline .

JAC-ANTIMICROBIAL RESISTANCE, 2021, 3 (02)

← 1 2 3 →